Determining the Predictive Impact of Donor Parity on the Outcomes of Human Leukocyte Antigen Matched Hematopoietic Stem Cell Transplants: a Retrospective, Single-center Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Mar 8

PMID 38454927

Authors

Mojtaba Azari

Maryam Barkhordar

Tanaz Bahri

Soroush Rad

Hosein Kamranzadeh Fumani

Seied Asadollah Mousavi

Sahar Tavakoli Shiraji

Morteza Azari

Parisa Shafaroudi

Mohammad Vaezi

Affiliations

Soon will be listed here.

Abstract

Introduction: Donor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor.

Methods: We evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen.

Results: A total of 1103 allo-HSCT recipients were included. 188 (17%) had transplants from parous female donors, whereas 621 (56.30%) and 294 (26.70%) received transplants from male and nulliparous female donors, respectively. HSCTs from parous female donors compared to male and nulliparous females were associated with a significantly higher incidence of grade III-IV acute (a) GVHD (55.27% vs. 11.34 and 10.84%) and extensive chronic (c) GVHD (64.32% vs. 15.52 and 13.65%), as well as lower relapse incidence (RI).

Discussion: This study finds that while parous female donors are associated with higher incidences of grade III-IV aGVHD and extensive cGVHD post-allo-HSCT, the advantages, such as a lower RI, outweigh the risks. The results of our study provide valuable insights for donor selection.

Citing Articles

A New Tool Supporting the Selection of the Best Hematopoietic Stem Cell Donor by Modelling Local Own Real-World Data.

Crocchiolo R, Cacace S, Milone G, Sarina B, Cupri A, Leotta S J Clin Med. 2024; 13(22).

PMID: 39598013 PMC: 11594974. DOI: 10.3390/jcm13226869.

References

Randolph S, Gooley T, Warren E, Appelbaum F, Riddell S . Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2003; 103(1):347-52. DOI: 10.1182/blood-2003-07-2603. View

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J . Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017; 10(1):130. PMC: 5483262. DOI: 10.1186/s13045-017-0498-8. View

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

Kanda J, Ichinohe T, Matsuo K, Benjamin R, Klumpp T, Rozman P . Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion. 2009; 49(4):624-35. DOI: 10.1111/j.1537-2995.2008.02043.x. View

Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P . Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003; 8(12):674-82. DOI: 10.1053/bbmt.2002.v8.abbmt080674. View

Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J . Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol. 1986; 63(2):231-9. DOI: 10.1111/j.1365-2141.1986.tb05545.x. View

Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J . Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007; 13(5):601-7. DOI: 10.1016/j.bbmt.2007.01.073. View

Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U . Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. Biol Blood Marrow Transplant. 2014; 21(4):713-9. PMC: 4359638. DOI: 10.1016/j.bbmt.2014.12.018. View

Gupta V, Tallman M, He W, Logan B, Copelan E, Gale R . Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010; 116(11):1839-48. PMC: 3173984. DOI: 10.1182/blood-2010-04-278317. View

10.

Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J . CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013; 122(19):3359-64. DOI: 10.1182/blood-2013-05-499830. View

11.

Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S . Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998; 22(8):755-61. DOI: 10.1038/sj.bmt.1701423. View

12.

Verdijk R, Kloosterman A, Pool J, van de Keur M, Naipal A, van Halteren A . Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood. 2003; 103(5):1961-4. DOI: 10.1182/blood-2003-05-1625. View

13.

van Kampen C, van Beelen E, Roelen D, Claas F . Pregnancy can induce long-persisting primed CTLs specific for inherited paternal HLA antigens. Hum Immunol. 2001; 62(3):201-7. DOI: 10.1016/s0198-8859(01)00209-9. View

14.

Flowers M, Pepe M, Longton G, Doney K, Monroe D, Witherspoon R . Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol. 1990; 74(4):492-6. DOI: 10.1111/j.1365-2141.1990.tb06340.x. View

15.

Kollman C, Spellman S, Zhang M, Hassebroek A, Anasetti C, Antin J . The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2015; 127(2):260-7. PMC: 4713163. DOI: 10.1182/blood-2015-08-663823. View

16.

Kim H, Zhang M, Woolfrey A, Martin A, Chen J, Saber W . Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica. 2016; 101(10):1260-1266. PMC: 5046656. DOI: 10.3324/haematol.2016.147645. View

17.

Barkhordar M, Kasaeian A, Janbabai G, Kamranzadeh Fumani H, Tavakoli S, Rashidi A . Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. Front Immunol. 2022; 13:921293. PMC: 9388846. DOI: 10.3389/fimmu.2022.921293. View

18.

Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, Kurokawa M . The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int. 2011; 24(5):469-76. DOI: 10.1111/j.1432-2277.2011.01229.x. View

19.

Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304. DOI: 10.1097/00007890-197410000-00001. View

20.

Przepiorka D, Smith T, Folloder J, Khouri I, Ueno N, Mehra R . Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999; 94(4):1465-70. View